ZFP598 Activators
Chemical activators of ZFP598 function through diverse molecular pathways to modulate the protein's activity via phosphorylation. Forskolin acts by triggering adenylate cyclase, which ramps up the production of cAMP within the cell. Elevated cAMP, in turn, activates protein kinase A (PKA). Once active, PKA phosphorylates various substrates, including ZFP598, thereby modulating its activity. Similarly, IBMX raises cAMP levels by inhibiting phosphodiesterases, leading to PKA activation and subsequent phosphorylation of ZFP598. Dibutyryl-cAMP, a cAMP analog, directly stimulates PKA, bypassing upstream signaling, while Zaprinast and Rolipram, by selectively inhibiting specific phosphodiesterase enzymes, also increase cAMP and thus support the PKA-mediated phosphorylation of ZFP598.
On a different pathway, PMA activates protein kinase C (PKC), which phosphorylates a broad array of proteins. Through PKC's action, ZFP598 can be phosphorylated and activated. Anisomycin, by stimulating MAP kinase pathways, can lead to the phosphorylation of ZFP598 due to the kinase's broad role in stress and translational response signaling. Inhibitors of protein phosphatases like Okadaic Acid and Calyculin A contribute to ZFP598's phosphorylation by preventing dephosphorylation, ensuring that ZFP598 remains in an active state. Sodium Orthovanadate operates similarly by inhibiting tyrosine phosphatases, thus promoting a phosphorylated state of proteins that could encompass ZFP598. Calcium ionophores such as A23187 (Calcimycin) and Ionomycin, by increasing intracellular calcium levels, activate calcium-dependent signaling pathways, which can include the phosphorylation of ZFP598, resulting in its activation. These chemical activators, through their actions on different enzymes and signaling pathways, orchestrate a complex regulation of ZFP598 via phosphorylation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as an inhibitor of phosphodiesterases, preventing the breakdown of cAMP. This results in increased levels of cAMP within the cell, which can activate PKA. PKA, in turn, can phosphorylate ZFP598, facilitating its activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a variety of proteins. Phosphorylation by PKC has been shown to activate certain proteins, and ZFP598 could be activated as a result of PKC's action, given its association with PKC-regulated pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases 1 and 2A. By inhibiting these phosphatases, Okadaic Acid prevents dephosphorylation, maintaining proteins in a phosphorylated state, which could include ZFP598, resulting in its continued activation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin activates MAP kinase pathways, which can lead to the phosphorylation of various proteins involved in stress and translational responses. ZFP598, being associated with translational machinery, can be activated through this pathway by MAP kinase-mediated phosphorylation. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Sodium Orthovanadate inhibits tyrosine phosphatases, which increases the phosphorylation state of target proteins. ZFP598 activation may be facilitated by its phosphorylation through pathways influenced by this inhibition. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is an inhibitor of protein phosphatases, like Okadaic Acid. It can maintain ZFP598 in a phosphorylated state by inhibiting dephosphorylation, which is a mechanism that can lead to the activation of ZFP598. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast selectively inhibits phosphodiesterase 5, leading to an increase in cAMP levels. The increase in cAMP can subsequently activate PKA, which may phosphorylate and activate ZFP598, as part of the cAMP-dependent signaling pathway. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, increasing cAMP levels. The elevated cAMP activates PKA, and PKA can phosphorylate ZFP598, leading to its activation within the cellular signaling pathways where PKA plays a role. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cAMP analog that activates PKA. Activated PKA can then phosphorylate ZFP598, which is a potential activation mechanism for this protein within PKA-regulated pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as an ionophore that increases intracellular calcium levels. This elevation in calcium can activate calcium-dependent signaling pathways, which might include phosphorylation events leading to the activation of ZFP598. | ||||||